多免疫代谢矿:NP通过抑制Leucine/PI3K/Akt/mTOR信号通路来预防ALI中的超免疫性
Mantong Zhao1, Jiazi Lin1, Xiao Wang1
1Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, Department of Biology, Faculty of Arts and Sciences, Beijing Normal University, Zhuhai, 519087, China; School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Free radical biology & medicine
|October 6, 2024
概括
尼坎德拉植物提取物 (NPE) 通过重塑免疫代谢和抑制炎症,防止急性肺损伤 (ALI). 它调节了Leucine/PI3K/Akt/mTOR通路,抑制了有害的免疫细胞分化.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 代谢学 代谢学 代谢学
背景情况:
- 急性肺损伤 (ALI) 是一个重大的全球健康挑战.
- 在中国传统医学中使用的Nicandra physalodes (NP) 对ALI具有潜在的治疗特性,但其机制尚不清楚.
研究的目的:
- 调查尼坎德拉植物提取物 (NPE) 对小鼠的脂多糖 (LPS) 诱导的ALI的保护作用和分子机制.
- 阐明免疫代谢和特定信号通路在NPE治疗作用中的作用.
主要方法:
- 网络药理学预测了活性成分和途径.
- UPLC-Q-TOF-MS/MS分析了NPE的组成.
- (1) H-NMR 免疫代谢剂评估了肺部,血清和便组织的代谢变化.
- IHC,IF,RT-qPCR和ELISA验证了关键的蛋白质和基因表达.
主要成果:
- NPE含有尼坎德伦,维他诺化物A和贝卡林.
- 在ALI小鼠中,NPE治疗减少了肺损伤,胀和炎症细胞透.
- 通过PI3K/Akt/mTOR通路,NPE增强了自和抑制了由Th1/Th17细胞驱动的炎症.
- 免疫代谢分析显示,NPE通过重塑免疫代谢来逆转ALI诱导的白蛋白抗性.
结论:
- 通过重塑免疫代谢和调节Leucine/PI3K/Akt/mTOR信号通路,NPE显示出对ALI的保护作用.
- NPE 抑制了 Th1/Th17 细胞分化,为其在治疗 ALI 的临床使用提供了科学依据.
相关概念视频
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...


